Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT.
about
Amantadine therapy for chronic hepatitis CRibavirin increases mitogen- and antigen-induced expression of CD40L on CD4+ T cells in vivoBenefit of hepatitis C virus core antigen assay in prediction of therapeutic response to interferon and ribavirin combination therapyEffects of immunosuppression and organ transplantation on the natural history and immunopathogenesis of hepatitis C virus infection.Management of viral hepatitis C.Review article: indicators and predictors of response to anti-viral therapy in chronic hepatitis C.Current therapy of hepatitis C.Effect of cytokine gene polymorphism on histological activity index, viral load and response to treatment in patients with chronic hepatitis C genotype 3.Chronic hepatitis C--Swedish experts' meeting recommends combination treatment.Retreatment for 24 vs 48 weeks with interferon-alpha2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone.Monitoring virological responses to interferon-ribavirin and interferon monotherapy of chronic hepatitis C re-treated due to relapse or non-response.Factors predicting interferon treatment response in patients with chronic hepatitis c: late viral clearance does not preclude a sustained response.Hepatitis C virus kinetics during induction and standard 3 times a week interferon-alpha therapy.Frequencies of HCV-specific effector CD4+ T cells by flow cytometry: correlation with clinical disease stages.Induction therapy with consensus interferon (CIFN) does not improve sustained virologic response in chronic hepatitis C.First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline.Interferon-alpha plus ribavirin for 12 months increases the sustained response rates in chronic hepatitis C relapsers.Is delayed normalization of alanine aminotransferase a poor prognostic predictor in chronic hepatitis C patients treated with a combined interferon and ribavirin therapy?Low daily dosage of interferon for 1 year after HCV-related end-therapy response. A randomized-controlled study.Dynamic decision analysis to determine optimal treatment duration in chronic hepatitis C.Effects of interferon and ribavirin combination therapy on CD4+ proliferation, lymphocyte activation, and Th1 and Th2 cytokine profiles in chronic hepatitis C.A randomized controlled trial of amantadine plus interferon-alpha2a vs. interferon-alpha2a alone in naive patients with chronic hepatitis C randomized according to the early virological response to interferon-alpha2a monotherapy.Treatment with ribavirin and interferon-alpha reduces interferon-gamma expression in patients with chronic hepatitis C.Interferon alfa-2b plus ribavirin for chronic hepatitis C patients who have not responded to interferon monotherapy.Quantitative HBV DNA levels as an early predictor of nonresponse in chronic HBe-antigen positive hepatitis B patients treated with interferon-alpha
P2860
Q27473307-BE726D00-B537-46B9-9968-F27B5B169EE1Q27480732-7B5464DE-4FB3-4FA2-815E-A217FAE5A2ACQ33592250-B6F740F3-2F87-44BC-90C7-E51F42B85D02Q34294938-3789A40C-3491-4D89-AC20-9EFDBA9997B8Q34631375-32DDE755-89AF-4327-9049-0BACFB5305BCQ35086844-6051BFA8-8B92-46C6-8A1D-B0BFD8418672Q36510682-E55827DF-0CE8-4D75-BD85-3FE6EB79495BQ42997726-1533DDE3-2D26-438F-8BEC-FC472CD4C4B9Q43000772-6E51EF02-6ABE-4776-ACFC-212E7E3081DFQ43001306-9EF5C92C-B98C-4FE3-8500-3E6B61E339E7Q43030170-D00CCD4F-A198-4BD2-9C90-ED164CE5CB61Q43031070-09EBD930-BE34-4508-B6C2-658619BD12E3Q43035797-CE954925-D76A-4AD4-9CAF-9559A481EC0BQ43036009-575AED14-9A7B-49DF-AE56-253F39D3411FQ43039938-927E39EB-796A-42D7-8BB1-96AE08B2D2A3Q43039947-A87645A5-FBB9-4557-B75C-991AA9AFEDEBQ43892504-A1126D63-4006-4B5F-9C92-45BE39E7820EQ44210299-50F14248-6454-4FB9-9D02-F20E340EDE3FQ44778300-F05D32F1-56CB-4425-A538-BAEF2BCC2A5DQ45289820-1D3A42F3-D6EC-4E26-BF64-CB9DFD831EBCQ47675296-F6986E38-9DA6-4C10-A849-8CC1386C7FCDQ48036349-2E47A67D-4BAA-4C27-BC9A-4414EA937B94Q50585994-E078E2D7-70FF-49DA-9584-8CDC736D3023Q50586981-6D9C21FE-5B7F-4345-A459-8C3BAB7D2211Q58376712-CA0B886A-0B53-4731-9215-28AFDC7A16F8
P2860
Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Early prediction of response i ...... HCV RNA at 4 weeks versus ALT.
@en
type
label
Early prediction of response i ...... HCV RNA at 4 weeks versus ALT.
@en
prefLabel
Early prediction of response i ...... HCV RNA at 4 weeks versus ALT.
@en
P2093
P1476
Early prediction of response i ...... HCV RNA at 4 weeks versus ALT.
@en
P2093
H G Niesters
J T Brouwer
S W Schalm
P304
P356
10.1016/S0168-8278(99)80061-0
P50
P577
1999-02-01T00:00:00Z